Skip to content

COMPARISON OF OUTCOME OF HYPOXIC ISCHEMIC ENCEPHLOPATHY MANAGED WITH COMBINATION OF MAGNESIUM SULPHATE AND MELATONIN VERSUS MAGNESIUM SULPHATE ALONE

COMPARISON OF OUTCOME OF HYPOXIC ENCEPHLOPATHY MANAGED WITH MgSO4 AND MELATONIN VERSUS MgSO4 ALONE

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07652801
Enrollment
80
Registered
2026-06-17
Start date
2026-07-01
Completion date
2026-12-31
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIE - Hypoxic - Ischemic Encephalopathy

Brief summary

COMPARISON OF OUTCOME OF HYPOXIC ISCHEMIC ENCEPHALOPATHY MANAGED WITH COMBINATION OF MAGNESIUM SULPHATE AND MELATONIN VERSUS MAGNESIUM SULPHATE ALONE Participants of group A will have 3 doses of MgSO4 infusion at rate of 250mg/kg per day intravenous over 1hour on day 0,1,2 Participants of group B will have 5 doses of Melatonin 10mg/kg for 5days along with MgSO4. They will undergo reassessment of arterial PH and serum LDH after completion of therapy. They will be followed for length of hospital stay and time until feed is initiated.

Interventions

Three doses of MgSO4 infusion at the rate of 250mg/kg per day intravenous over 1 hour on days 0, 1, and 2

DRUGMelatonin , Mgso4

Five doses of melatonin along with three doses of MgSO4 infusion at the rate of 250mg/kg per day intravenous over 1 hour on days 0, 1, and 2

Sponsors

University of Child Health Sciences and Children's Hospital, Lahore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 28 Days
Healthy volunteers
No

Inclusion criteria

* Both genders * Born at term i.e \>37weeks gestation * With APGAR score\<5 at 1min * Umblical artery acidemia(PH\<7 or base deficit\>12mmol/L * Evidence of atleast moderate grade ofHIE on sarnat scoring.

Exclusion criteria

* With congenital anamolies * Intrauterine growth retadation * suspicion of neonatal sepsis * Congenital heart disese and those with IEM.

Design outcomes

Primary

MeasureTime frameDescription
1.Change in PH 2.Serum LDH(U/L)5 DAYSchange in arterial PH,SERUM LDH

Contacts

CONTACTdr akasha rehman rehman, MD Pedatrics
akasharehman55@gmail.com923041867246
CONTACTalia ahmed, FCPS,MRCPCH,FRCPCH
alia_ahmad99@yahoo.com923344081996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026